To Evaluate the Safety and Tolerability of GS3-007a Oral Solution in a Multi-dose, Randomized, Open, Single-center Study in Healthy Chinese Adult Subjects.
Latest Information Update: 14 Nov 2023
At a glance
- Drugs GS3-007 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors GeneScience Pharmaceuticals
Most Recent Events
- 08 Nov 2023 Status changed from not yet recruiting to completed.
- 29 Jun 2023 New trial record